Sebastian Gensior

Introduction In today's tough biotech funding climate, many public biotechs have resorted to creative financing combos to stay afloat. Rather than relying on a single source of cash, a distressed company might simultaneously tap a term loan (venture debt), execute a royalty monetization deal, and secure an equity

Biotech and Healthcare Transactions Report: November 17-21, 2025 Abbott's $21 billion Exact Sciences acquisition dominated a busy week that saw $24.6 billion in M&A transactions and $656.5 million in venture financings, signaling renewed dealmaking momentum. The week delivered one mega-deal and four mid-sized acquisitions

London has just wrapped up the Jefferies Global Healthcare Conference 2025, now firmly established as Europe’s largest healthcare investment gathering. Over four days (November 17–20, 2025), around 4,500 participants from 50 countries and 950 companies converged on the city. Often dubbed the “J.P. Morgan of Europe,

SanegeneBio is a venture-backed biotechnology company founded in 2021, focused on developing RNA interference (RNAi) therapeutics for cardiometabolic and immunological diseases. Headquartered in Suzhou, China with R&D operations in Boston and Shanghai, the company is led by a team of RNAi veterans leveraging a proprietary Ligand and Enhancer

We held our first royalty-financing event in London during the Jefferies Healthcare Conference, a meeting better known for quick negotiations than for slow examinations of cash-flow structures. The contrast worked. While the main conference discussed valuation cycles, clinical inflection points and the temperament of public markets, our session attracted people

Introduction The pharmaceutical royalty market has become increasingly sophisticated, with specialized funds and institutional investors acquiring rights to future royalty streams from universities, biotech companies, and research institutions across borders. When a U.S.-based buyer acquires royalty rights from sellers in Europe—particularly in the United Kingdom, Germany, France,

The biotech liquidation market showed signs of maturation during September-November 2025, with established players pausing acquisition activity while market distress indicators reached unprecedented levels. Tang Capital's Concentra Biosciences completed no new deals after a frenetic July-August period that saw three major acquisitions totaling over $500 million close. Meanwhile,

A new financing model proposes to bridge biotech's "valley of death" by combining adaptive platform trials with royalty payments. The math looks compelling on paper—28% returns for investors, faster drug development for patients. But can it actually work? The Innovation That Caught My Eye When

The biotech sector experienced one of its most intense dealmaking periods of 2025 during November 10-15, with over $25 billion in total transaction value across M&A, licensing, and venture financing. Eli Lilly emerged as the week's most aggressive dealmaker with three partnerships totaling $3.2 billion

Introduction: Raising Capital for Defense In the biotech industry's recent downturn, many companies have faced plummeting valuations – over 220 Nasdaq-listed biotechs traded below their net cash by late 2023. Desperate to fund R&D without diluting shareholders at rock-bottom prices, these firms increasingly turned to royalty financing